City of Hope and Osel Announce Live Biotherapeutic Product CBM588 May Enhance Efficacy of Immunotherapy for Patients With Metastatic Kidney Cancer

LOS ANGELES & MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Phase 1 trial data showing use of live biotherapeutic CBM588 and immunotherapy medicine can improve survival in patients with metastatic kidney cancer

Click to view original post